Soligenix (0A6I) Stock Overview

A late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. More details

0A6I fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 10.5% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

0A6I Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.

View narrative

Lou_Basenese

Community Contributor

US$7.6FV • 72.5% undervalued

5022.2%Revenue growth p.a.

3.3k

19d ago

Soligenix, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Soligenix
Historical stock prices
Current Share Price	US$1.30
52 Week High	US$6.20
52 Week Low	US$1.01
Beta	1.94
1 Month Change	9.24%
3 Month Change	-8.45%
1 Year Change	-35.95%
3 Year Change	-95.20%
5 Year Change	-99.64%
Change since IPO	-99.65%

Recent updates

Shareholder Returns

	0A6I	GB Biotechs	GB Market
7D	14.0%	-2.1%	-0.7%
1Y	-36.0%	37.8%	26.1%

Return vs Industry: 0A6I underperformed the UK Biotechs industry which returned 37.8% over the past year.

Return vs Market: 0A6I underperformed the UK Market which returned 26.1% over the past year.

Price Volatility

Is 0A6I's price volatile compared to industry and market?
0A6I volatility
0A6I Average Weekly Movement	7.9%
Biotechs Industry Average Movement	8.2%
Market Average Movement	5.7%
10% most volatile stocks in GB Market	11.9%
10% least volatile stocks in GB Market	3.2%

Stable Share Price: 0A6I has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0A6I's weekly volatility has decreased from 30% to 8% over the past year.

About the Company

Founded	Employees	CEO	Website
1987	14	Christopher Schaber	www.soligenix.com

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis.

Soligenix, Inc. Fundamentals Summary

How do Soligenix's earnings and revenue compare to its market cap?
0A6I fundamental statistics
Market cap	US$13.81m
Earnings (TTM)	-US$11.08m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.2x

P/E Ratio

Is 0A6I overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A6I income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$11.08m
Earnings	-US$11.08m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-1.08
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 0A6I perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/22 20:48
End of Day Share Price	2026/04/22 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Soligenix, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Andrew D'Silva	B. Riley Securities, Inc.
Keith Markey	Griffin Securities

Soligenix (0A6I) Stock Overview

Risk Analysis

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Soligenix, Inc. Competitors

Theracryf

Solvonis Therapeutics

Aptamer Group

Cardiogeni

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

Soligenix Inc. Announces Positive Clinical Results For HyBryte In Comparative Study Against Valchlor In Treatment Of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Presents Hybryte Treatment Results At US Cutaneous Lymphoma Consortium Annual Workshop

Soligenix, Inc. Receives Promising Innovative Medicine Designation for SGX945 in the United Kingdom

Soligenix, Inc. Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for Sgx945 for the Treatment of Behcet's Disease

New major risk - Revenue and earnings growth

Recent updates

New major risk - Revenue and earnings growth

Soligenix Inc. Announces Positive Clinical Results For HyBryte In Comparative Study Against Valchlor In Treatment Of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Presents Hybryte Treatment Results At US Cutaneous Lymphoma Consortium Annual Workshop

Soligenix, Inc. Receives Promising Innovative Medicine Designation for SGX945 in the United Kingdom

Soligenix, Inc. Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for Sgx945 for the Treatment of Behcet's Disease

New major risk - Revenue and earnings growth

Soligenix, Inc. has filed a Follow-on Equity Offering in the amount of $3.45 million.

Soligenix, Inc. Announces Positive Clinical Results from Phase 2 Trial of Sgx945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford)

Soligenix Inc. Announces Audio Press Release on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte™? for the Treatment of Cutaneous T-Cell Lymphoma

New major risk - Financial position

Soligenix Achieves Important Safety Milestone in Its Confirmatory Phase 3 Clinical Trial of Hybryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc. has completed a Follow-on Equity Offering in the amount of $7.500006 million.

New major risk - Market cap size

Soligenix, Inc. has filed a Follow-on Equity Offering in the amount of $7.999998 million.

Soligenix, Inc. Announces Publication Recommending Long-Term High Temperature Stability of Protein Subunit Vaccines forbola and Related Viruses

Soligenix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for its Common Stock

Soligenix Inc. Announces Audio Press Release on Promising First-Line Therapy for Rare Skin Cancer

Soligenix, Inc. Completes its Phase 2a Proof of Concept Study Evaluating SGX945 (Dusquetide) in Treatment of Behcet's Disease and Achieves Study Objective of Demonstrating Biological Efficacy

Soligenix, Inc. Announces Synthetic Hypericin Successfully Manufactured At Sterling Pharma Solutions

Soligenix, Inc. Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte in Ongoing Clinical Trials

First quarter 2025 earnings released: US$1.06 loss per share (vs US$2.91 loss in 1Q 2024)

Soligenix, Inc., Annual General Meeting, Jun 20, 2025

Soligenix, Inc. Announces Interim Results from the Ongoing Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte

No longer forecast to breakeven

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte

Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Second quarter 2024 earnings released: US$1.31 loss per share (vs US$3.56 loss in 2Q 2023)

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.36 loss in 1Q 2023)

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Full year 2023 earnings released: US$0.79 loss per share (vs US$4.81 loss in FY 2022)

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Insufficient new directors

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$1.15 loss in 3Q 2022)

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Insufficient new directors

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings released: US$0.36 loss per share (vs US$1.52 loss in 1Q 2022)

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Insufficient new directors